Search
for
Sort by
Research 601–630 of 613
- Hair & Cutaneous Development
- Abstract CN06-04: The hedgehog signaling pathway in cancer.
- Pharmacogenetics of the Androgen Metabolic Pathway
- [Molecular cloning of full-long cDNA sequences encoding hairless gene in the Kunming mouse].
- Treatment of Del(5q) Myelodysplastic Syndrome with All-Trans-Retinoic Acid and Tocopherol-α.
- Certain Cancer Myths Endure, with Impact on Treatment, Prevention, Screening
- Clinical and metabolic characteristics of males with early-onset androgenetic alopecia.
- Serum Ferritin Levels amongst Individuals with Androgenetic Alopecia in Ile-Ife, Nigeria.
- Androgenetic Alopecia and Metabolic Syndrome: Is Alarin a Missing Link?
- Up-regulation of androgen receptor by heat shock protein 27 and miR-1 induces pathogenesis of androgenic alopecia.
- Pilot study: genetic distribution of AR, FGF5, SULT1A1 and CYP3A5 polymorphisms in male Mexican population with androgenetic alopecia.
- Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow.
- [Androgenetic alopecia].
- Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors
- Present Chemotherapy Induced Alopecia and Research in Future
- Index
- Alopecia in patients treated with molecularly targeted anticancer therapies
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Identifying the supportive care needs of men and women affected by chemotherapy-induced alopecia? A systematic review
- Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects
- A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with advanced or metastatic salivary duct carcinoma – the DUCT study protocol
- Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm
- Management of Toxicities of Targeted Therapies
- Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis
- Management of Cutaneous and Extracutaneous Side Effects of Smoothened Inhibitor Therapy for Advanced Basal Cell Carcinoma
- Dermatologic Adverse Events from Cancer Treatments
- The efficacy of scalp cooling in patients receiving chemotherapy for primary gynecologic cancers: a randomized controlled trial
- Radiotherapy-Induced Skin Fibrosis: Pathophysiology, Emerging Therapeutics, and the Role of Dermatology